Top Flu Vaccine Brands to Keep You Protected and Healthy

As the flu season approaches, many individuals are seeking the most effective vaccines to protect themselves and their loved ones. Choosing the right vaccine can be a daunting task given the variety of brands available, each offering unique formulations and benefits. Among the top contenders are well-reputed pharmaceutical companies known for their rigorous testing and efficacy. To help you make an informed decision, we have compiled a list of the best flu vaccine brands, highlighting their key features below.

Illustration of flu vaccine

Best brands of flu vaccine in 2025

Sanofi Pasteur

Sanofi Pasteur is a leading producer of flu vaccines, contributing significantly to the global market. In 2024, the flu vaccine market, dominated by quadrivalent vaccines with an 84% market share, is expected to grow at a CAGR of 6.7% from 2024 to 2034, with Sanofi Pasteur being a key player. The company's advanced government healthcare initiatives and strong market presence, particularly in North America where it holds a 63.3% market share, drive its success. Sanofi Pasteur's vaccines, such as QIVe and QIVr, are widely used and promoted, despite some logistical challenges in supply due to global demand. The company's collaboration with other firms, like Novavax, to develop novel COVID-19-Influenza combination vaccines further enhances its position in the vaccine market. For more information on their vaccines and initiatives, visit Sanofi Pasteur's official website.

GlaxoSmithKline

GlaxoSmithKline (GSK) is a leading producer of flu vaccines, known for its reliable and effective products such as FLULAVAL and FLUARIX. For the 2024-25 flu season, GSK anticipates distributing over 36 million doses of its trivalent influenza vaccines in the US, following FDA approval and alignment with WHO recommendations. GSK's vaccines are indicated for people six months of age and older and are available in 0.5mL, single-dose, pre-filled syringes. The company's commitment to annual flu immunization is supported by the CDC's recommendation for yearly vaccination for nearly all people over six months old. GSK's vaccines have been instrumental in protecting against the flu, with the CDC estimating that flu vaccines reduce the risk of illness by about 40% to 60% when the strains match the circulating viruses.

Seqirus

CSL Seqirus is a leading global producer of influenza vaccines, dedicated to reducing the severity and impact of influenza. As one of the world's largest influenza vaccine companies, Seqirus was formed through CSL Limited's acquisition of the Novartis influenza vaccine business and its vaccine subsidiary, bioCSL. The company's vaccines protect millions of people annually, with a strong focus on quadrivalent vaccines that have dominated the market with a share of 86.77% due to their high efficacy and cost-effectiveness. Seqirus's commitment to innovation is evident in the launch of novel vaccines, such as the first needle-free nasal influenza vaccine in collaboration with the Serum Institute of India. Their vaccines are crucial in regions like North America, where they contribute significantly to the market, which held a 53.35% share in 2023. For more information about their innovations, visit the CSL Seqirus website.

AstraZeneca

AstraZeneca is a leading producer of flu vaccines, known for its high-quality and effective products. The company has been instrumental in the global effort to combat influenza, particularly through its participation in the World Health Organization's (WHO) annual influenza strain selection process. For the 2024-2025 season, AstraZeneca, along with other manufacturers, is prepared to remove the B/Yamagata virus strain from their influenza vaccines, ensuring alignment with the latest WHO recommendations. AstraZeneca's vaccines have demonstrated significant efficacy, with some studies showing reductions in culture-confirmed influenza illness by up to 57.7% in previously unvaccinated individuals. The company's commitment to vaccine development and distribution is crucial in maintaining public health, especially given the global influenza vaccine market's projected growth at a CAGR of 6.98% from 2024 to 2030. Learn more about AstraZeneca's influenza vaccines and their contributions.

Pfizer

Pfizer, in collaboration with BioNTech, is at the forefront of developing innovative influenza vaccines, demonstrating robust immunogenicity and efficacy. For the 2023-2024 season, their mRNA-based influenza vaccine candidates have shown promising results, with vaccine effectiveness (VE) against influenza A ranging from 27% to 46% in outpatient settings for adults and up to 59% for children and adolescents. Their combination vaccine approach, integrating both influenza and COVID-19 protection, has also shown significant potential, with Phase 3 trials indicating strong immunogenicity against multiple respiratory diseases. Pfizer's commitment to vaccine development aims to reduce the burden of influenza, which causes an estimated 140,000 to 710,000 hospitalizations and 12,000 to 52,000 deaths annually. Their ongoing research and clinical trials underscore their position as a leading producer of flu vaccines.

Novartis

Novartis, now part of CSL Limited's subsidiary Seqirus, was a pioneering producer of flu vaccines, particularly notable for its cell-based influenza vaccine facility in Holly Springs, North Carolina, which could produce up to 150 million doses of a monovalent vaccine within 6 months of a pandemic declaration. This facility, dedicated in 2011, marked a significant advancement in influenza vaccine manufacturing, offering a more flexible and faster alternative to traditional egg-based production methods. Novartis's cell-based vaccines, such as Optaflu, were already licensed in Europe and were set to be filed for FDA approval in the U.S. The acquisition by CSL Limited in 2015 further strengthened the global position of the combined business, making it the second-largest player in the $4 billion global influenza vaccine industry. For more information, visit the Seqirus website.

Merck & Co.

Merck & Co., known as MSD outside the US and Canada, is a leading producer of flu vaccines, contributing significantly to global health through innovative vaccine technologies. The company has made notable advancements, such as the approval of the NOBIVAC® NXT Canine Flu H3N2 vaccine, which represents a breakthrough in RNA-particle technology for canine influenza. Merck's commitment to research and development has been consistent, with the company being at the forefront of vaccine innovation for over a century. Their vaccines are available in over 150 markets, and they continue to invest extensively in R&D to improve animal and human health. Merck's global presence and innovative solutions make it a trusted name in the vaccine market.

Abbott Laboratories

Abbott Laboratories is a leading global provider of flu vaccines, with its Influvac brand offering protection against the flu in over 75 countries since 1949. The company has expanded its portfolio with the launch of Influvac Tetra, a quadrivalent vaccine that protects against four different flu viruses, enhancing protection and peace of mind for consumers. Quadrivalent vaccines, such as Influvac Tetra, dominate the market with a significant share due to their high efficacy, cost-effectiveness, and easy availability, with a market share of around 58.2% to 86.77% in recent years. Abbott's flu vaccines are particularly popular in emerging markets, including India, and hold halal certification, further expanding their use. The global influenza vaccine market, in which Abbott is a key player, is projected to grow at a CAGR of 6.98% to 7.6% from 2024 to 2030. For more insights into Abbott's proven flu fighters, visit their official page.

Bharat Biotech

Bharat Biotech is a leading biotechnology company renowned for its innovative and effective flu vaccines. The company has developed India's first indigenously produced cell-culture H1N1 swine flu vaccine, HNVAC(tm), which has been proven safe and well-tolerated in extensive clinical trials. Bharat Biotech has also been at the forefront of COVID-19 vaccine development with COVAXIN(r), which demonstrated an overall efficacy of 77.8% in India's largest COVID-19 phase 3 clinical trial. With a capacity to produce almost 300 million doses per year, Bharat Biotech is committed to providing affordable and high-quality vaccines globally, particularly in lower middle-income countries. The company's vaccines are formulated to meet global distribution needs, including storage at 2-8°C and multi-dose vial policies to reduce wastage. For more information, visit their official website.

CSL Limited/CSL Seqirus

CSL Seqirus, a business of CSL Limited, is one of the world's largest and most innovative influenza vaccine companies, utilizing advanced technologies such as egg, cell, and adjuvant methods to produce a broad portfolio of differentiated vaccines. With state-of-the-art manufacturing facilities in the U.S., UK, and Australia, CSL Seqirus is capable of producing up to 150 million influenza vaccine doses in six months to support pandemic responses. The company has a significant global presence, supplying vaccines to over 20 countries and employing extensive R&D capabilities to enhance vaccine efficacy. In 2023, CSL Seqirus began shipping over 55 million doses of innovative influenza vaccines for the U.S. season, highlighting its commitment to public health. Through its partnership with BARDA, CSL Seqirus has developed cutting-edge vaccine candidates, including the first-ever adjuvanted, cell-based influenza vaccine approved by the FDA in 2020. For more details, explore their official website.